This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Avanos Medical (AVNS) Q1 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Avanos Medical's (AVNS) first-quarter results benefit from segmental contribution.
DENTSPLY SIRONA (XRAY) Posts Weak Q1 Preliminary Results
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter 2020 preliminary results reflect weak segmental performance and decline in revenues.
Integra (IART) Lags Q1 Earnings Estimates, Withdraws Outlook
by Zacks Equity Research
Integra's (IART) first-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.
Glaukos (GKOS) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Glaukos (GKOS) witnessed a contraction in gross margin but year-over-year revenue surge in Q1.
Bruker (BRKR) Q1 Earnings Miss Estimates, Guidance Suspended
by Zacks Equity Research
Bruker's (BRKR) first-quarter 2020 results reflect dismal performance by all segments and geographies due to coronavirus-led business disruptions.
Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) saw revenue growth in the Service and Other segment in Q1.
Amedisys (AMED) Q1 Earnings Beat, Operating Margin Falls
by Zacks Equity Research
Amedisys (AMED) notes that COVID-19 started impacting its volumes and costs beginning the second half of March.
NuVasive's (NUVA) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
NuVasive's (NUVA) operating segments experience slowdown in first-quarter volumes due to the coronavirus pandemic.
QIAGEN (QGEN) Q1 Earnings Lag Estimates, Operating Margin Up
by Zacks Equity Research
QIAGEN (QGEN) registered robust revenue growth across all geographies and each of its operating segments in Q1 despite the coronavirus-led economic crisis.
AmerisourceBergen (ABC) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal second-quarter earnings benefit from segmental growth.
Bio-Rad (BIO) Beats Q1 Earnings Estimates, Withdraws View
by Zacks Equity Research
Bio-Rad's (BIO) first-quarter 2020 results reflect strong segmental performance boosted by coronavirus-led increased testing demand.
Exact Sciences' (EXAS) Q1 Earnings Fall Y/Y, Margin Expands
by Zacks Equity Research
Exact Sciences' (EXAS) first-quarter 2020 results reflect strong performance by Screening segment amid the coronavirus-led economic crisis.
Nevro (NVRO) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Nevro's (NVRO) domestic revenues improved on a year-over-year basis in Q1.
Becton Dickinson (BDX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Becton Dickinson's (BDX) second-quarter results reflect solid performance by the core Life Sciences and Interventional segments.
Myriad Genetics (MYGN) Lags Q3 Earnings Estimates, Cancels View
by Zacks Equity Research
Myriad Genetics (MYGN) reports revenue declines in both reporting segments in Q3 resulting from coronavirus-led business disruptions.
CVS Health (CVS) Q1 Earnings Top Estimates, Costs Escalate
by Zacks Equity Research
Within CVS Health's (CVS) Retail/LTC, the coronavirus pandemic results in greater use of 90-day prescriptions and early refills of maintenance medications in the quarter.
Haemonetics (HAE) Q4 Earnings Lag Estimates, Margins Expand
by Zacks Equity Research
Haemonetics' (HAE) fourth-quarter fiscal 2020 results reflect strong performance by Plasma segment despite dismal overall performance during the coronavirus-led crisis.
Inogen's (INGN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inogen (INGN) reported growth in business-to-business international and domestic revenues in Q1.
DaVita (DVA) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
DaVita's (DVA) dialysis services in the United States showcased solid results in Q1.
Cardiovascular Systems (CSII) Reports Q3 Loss, Lower Margin
by Zacks Equity Research
Cardiovascular Systems (CSII) witnesses a significant decline in procedure volumes in Q3 for patients treated with orbital atherectomy devices.
PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results benefit from growth in Discover & Analytics Solutions segment. However, forex remains a woe.
Henry Schein (HSIC) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Henry Schein (HSIC) sees dismal performance by Dental arm in Q1 due to disruptions resulting from the coronavirus pandemic.
Tandem Diabetes (TNDM) Q1 Loss Widens, Revenues Top Estimates
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong domestic pump sales and the company's expansion in international markets boost the top line.
Teleflex (TFX) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Teleflex's (TFX) first-quarter 2020 results reflect sales growth across few major segments despite the coronavirus pandemic.
Hill-Rom's (HRC) Q2 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Hill-Rom (HRC) benefits from increased product demand due to the coronavirus outbreak.